1,5-Bis-(p-vinylbenzoylamido)anthrachinon | 29822-58-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 1,5-Bis-(p-vinylbenzoylamido)anthrachinon
• 英文别名: 4-ethenyl-N-[5-[(4-ethenylbenzoyl)amino]-9,10-dioxoanthracen-1-yl]benzamide
• CAS: 29822-58-0
• 化学式: C₃₂H₂₂N₂O₄
• 分子量: 498.538
• InChiKey: CLKXCNKMJQFUBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  92.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• CONTACT LENS MATERIAL
  申请人：Menicon Co., Ltd.

  公开号：EP1696257A1

  公开（公告）日：2006-08-30

  A contact lens material which has high oxygen permeability and mechanical strength, and extremely small in an amount of remaining unpolymerized monomers, at the same time, low in a water absorption ratio and excellent in shape stability of a lens is provided. The contact lens material comprises a copolymer obtained by polymerizing copolymer components containing a particular silicone-containing monomer, wherein the total residual amount of unpolymerized monomer components remaining in the copolymer based on the copolymer is at most 3.5 % by weight, an oxygen permeability coefficient of the copolymer is at least 130 × 10-11 (cm2/sec)·(mLO2)/(mL·mmHg), and a water absorption ratio of the copolymer is at most 0.3 % by weight.

  一种隐形眼镜材料具有较高的透氧性和机械强度，剩余的未聚合单体量极少，同时吸水率低，镜片形状稳定性极佳。该隐形眼镜材料包括一种通过聚合含有特定含硅单体的共聚物成分而获得的共聚物，其中基于共聚物的未聚合单体成分的总残留量最多为 3.5%（按重量计），共聚物的透氧系数至少为 130 × 10-11 (cm2/sec)-(mLO2)/(mL-mmHg) ，共聚物的吸水率最多为 0.3%（按重量计）。
• TREATING INFECTIONS AND SEQUELAE THEREOF WITH COMBINED DISSOCIATED GLUCOCORTICOID RECEPTOR AGONISTS AND ANTI-INFECTIVE AGENTS
  申请人：Bausch & Lomb Incorporated

  公开号：EP2049112A2

  公开（公告）日：2009-04-22
• Contact lens material
  申请人：Matsumoto Masihiro

  公开号：US20070149699A1

  公开（公告）日：2007-06-28

  A contact lens material which has high oxygen permeability and mechanical strength, and extremely small in an amount of remaining unpolymerized monomers, at the same time, low in a water absorption ratio and excellent in shape stability of a lens is provided. The contact lens material comprises a copolymer obtained by polymerizing copolymer components containing a particular silicone-containing monomer, wherein the total residual amount of unpolymerized monomer components remaining in the copolymer based on the copolymer is at most 3.5% by weight, an oxygen permeability coefficient of the copolymer is at least 130×10 −11 (cm 2 /sec)·(mLO 2 )/(mL·mmHg), and a water absorption ratio of the copolymer is at most 0.3% by weight.
• Contact Lens Material
  申请人：Matsumoto Masahiro

  公开号：US20090247662A1

  公开（公告）日：2009-10-01

  A contact lens material which has high oxygen permeability and mechanical strength, and extremely small in an amount of remaining unpolymerized monomers, at the same time, low in a water absorption ratio and excellent in shape stability of a lens is provided. The contact lens material comprises a copolymer obtained by polymerizing copolymer components containing a particular silicone-containing monomer, wherein the total residual amount of unpolymerized monomer components remaining in the copolymer based on the copolymer is at most 3.5% by weight, an oxygen permeability coefficient of the copolymer is at least 130×10 −11 (cm 2 /sec)·(mLO 2 )/(mL·mmHg), and a water absorption ratio of the copolymer is at most 0.3% by weight.
• [EN] COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR TRAITER, CONTRÔLER, RÉDUIRE OU AMÉLIORER LES INFECTIONS ET LES SÉQUELLES DE CELLES-CI
  申请人：BAUSCH & LOMB

  公开号：WO2008021728A2

  公开（公告）日：2008-02-21

  [EN] A composition for treating, controlling, reducing, ameliorating, or alleviating infections and their inflammatory sequelae comprises a dissociated glucocorticoid receptor agonist ("DIGRA") and an anti-infective agent, such as an antibacterial, antiviral, antifungal, antiprotozoal agent, or a combination thereof. The composition can be formulated for topical application, injection, or implantation.
  [FR] L'invention concerne une composition pour traiter, contrôler, réduire, améliorer ou soulager les infections et leurs séquelles inflammatoires. Ladite composition comprend un agoniste du récepteur des glucocorticoïdes dissocié (= DIGRA =) et un agent anti-infectieux, tel qu'un agent antibactérien, antiviral, antifongique, antiprotozoaire ou une combinaison de ceux-ci. La composition peut être formulée pour une application topique, une injection ou une implantation.